As of this week, the following products manufactured from expanded cord blood have been granted expedited pathways to FDA approval.
Parent's Guide to Cord Blood Foundation published a review of expanded cord blood products in May 2018.
|Manufacturer||Indication||FDA Expedited Path(s)|
|20180717||NiCord®||Gamida Cell||HSCT: Hematopoietic|
Stem Cell Transplants
|Nohla Therapeutics||HSCT engraftment,|
|20180823||Pneumostem®||Medipost||Bronchopulmonary Dysplasia||Orphan Drug|
|Regenerative Medicine Advanced Therapy (RMAT)|
|Inherited Metabolic Disorders||Regenerative Medicine Advanced Therapy (RMAT)|
These comments are submitted by website readers and are not endorsed by CellTrials.org, which is a project of Parent's Guide to Cord Blood Foundation. We screen the comments to keep out SPAM but we cannot review each one for accuracy.